Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients with systemic mastocytosis (SM) or Gastrointestinal Stromal Tumors (GIST).